Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index

- For the eighth consecutive year, Abbott (NYSE: ABT) has been named the industry leader in sustainability by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability. As the Global Industry Leader in the Health Care Equipment & Supplies sector, the company earned top scores for governanceeconomic and social performance. This is the 16 th consecutive year that Abbott has been recognized as a sustainability leader through its inclusion on the DJSI, including both the Dow Jones Sustainability World Index and North America Index.

"Sustainability in health care is about designing accessibility and affordability into the life-changing health technologies and products we create to help more people live healthier, fuller lives," said Robert B. Ford , president and chief executive officer, Abbott. "Abbott people have risen to that challenge this year, producing seven tests to help fight COVID-19 while continuing to advance new innovations in critical areas like diabetes, heart disease and nutrition, ultimately reaching nearly 2 billion people."

Abbott's overall score of 86 was more than triple the average score of 28 for other companies in its industry sector. Abbott achieved the top industry score in 11 of DJSI's 25 specific governance/economic, social and environmental criteria, including strategy to improve access to drugs or products, health outcome contribution, social reporting, human capital development, risk & crisis management, information security/cybersecurity & systems availability, customer relationship management, marketing practices, environmental reporting, operational eco-efficiency and occupational health and safety.

In addition to being included on DJSI, Abbott was named the 2020 World-Changing Company of the Year by Fast Company and was highlighted on Fortune's Change the World list. Abbott was also ranked No. 1 for social responsibility in its industry sector on Fortune's Most Admired Companies list for seven consecutive years (2014-2020), and was named one of the 100 Best Corporate Citizens by 3BL Media for 12 consecutive years (2009-2020).

Abbott's continued recognition demonstrates our longstanding commitment to sustainable, responsible business. Looking ahead, Abbott will further extend this commitment with the launch of its 2030 sustainability plan later this year. With forward-looking targets closely aligned to Abbott's purpose of helping people live fuller lives through better health, our 2030 plan will build a stronger, more sustainable Abbott that better serves the many people who depend on us.

To learn more about Abbott's strategic approach to sustainability, please visit abbott.com/sustainability .

For additional information on DJSI, please see the news release and DJSI Corporate Sustainability Assessment site.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Cision View original content: https://www.prnewswire.com/news-releases/abbott-named-industry-sustainability-leader-for-the-eighth-year-in-a-row-on-the-dow-jones-sustainability-index-djsi-301173727.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×